» Articles » PMID: 29040867

Long-term Follow-up of Anterior Thalamic Deep Brain Stimulation in Epilepsy: A 11-year, Single Center Experience

Overview
Journal Seizure
Publisher Elsevier
Specialty Neurology
Date 2017 Oct 18
PMID 29040867
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Anterior thalamic deep brain stimulation (ATN DBS) is an emerging, effective treatment for patients with drug-resistant epilepsy, but long-term results on its efficacy and safety are lacking. To evaluate the long-term efficacy and safety of ATN DBS treatment, as well as predictors of its success, in patients with drug-refractory epilepsy (DRE).

Method: We retrospectively studied clinical outcomes in 29 consecutive refractory epilepsy patients treated by a single DBS team (two neurosurgeons, four neurologists) over an 11-year period, for whom follow-up was performed for up to 137 months (mean, 74.9 months).

Results: The average participant was 30.7 (±10.4) years old and had epilepsy for 19.3 (±9.0) years. The mean preoperative frequency of disabling partial or generalized tonic-clonic seizures was 27.5 (±8.6, SE) seizures a month. The median percent seizure reduction was 71.3% at 1year, 73.9% at 2 years, and ranged from 61.8% to 80.0% over post-implant years 3 through 11 in the long-term study (overall 70% median reduction). In the 11-year study period, 13.8% (4/29) of subjects were seizure-free for at least 12 months during this time. There was only one symptomatic intracranial hemorrhage that happened during follow-up (3.4%). Infection requiring removal and later re-implantation of hardware occurred in only 1 of 30 patients (3.3%), who was subsequently excluded from our follow-up assessment. Hardware malfunction including lead disconnection occurred in 2 of 29 cases (6.9%). Revision of lead position to redeem poor clinical response was performed in 3 of 58 implanted leads (5.2%).

Conclusions: ATN DBS can be an effective therapy in a variety of patients with DRE. Importantly, we provide evidence that significant therapeutic efficacy can be sustained for up to 11 years. Neurological complications were rather rare, but long-term hardware-related complications should be followed arrectis auribus.

Citing Articles

Effect of deep brain stimulation on the severity of seizures and the quality of life in patients with multifocal drug-resistant epilepsy in Iran: A pilot review of local experience.

Bahadori A, Javadnia P, Davari A, Shafiee S, Ranji S, Sheikhvatan M Epilepsy Behav Rep. 2025; 29:100742.

PMID: 39906530 PMC: 11791334. DOI: 10.1016/j.ebr.2025.100742.


Efficacy and safety of deep brain stimulation in drug resistance epilepsy: A systematic review and meta-analysis.

Bahadori A, Javadnia P, Davari A, Sheikhvatan M, Ranji S, Shafiee S Neurosurg Rev. 2024; 47(1):855.

PMID: 39557745 DOI: 10.1007/s10143-024-03090-9.


The comparison of DBS and RNS for adult drug-resistant epilepsy: a systematic review and meta-analysis.

Li Q, Shan Y, Wei P, Zhao G Front Hum Neurosci. 2024; 18:1429223.

PMID: 38962148 PMC: 11220164. DOI: 10.3389/fnhum.2024.1429223.


Systematic review of rodent studies of deep brain stimulation for the treatment of neurological, developmental and neuropsychiatric disorders.

Zhang K, Matin R, Gorodetsky C, Ibrahim G, Venetucci Gouveia F Transl Psychiatry. 2024; 14(1):186.

PMID: 38605027 PMC: 11009311. DOI: 10.1038/s41398-023-02727-5.


Transient targeting of hypothalamic orexin neurons alleviates seizures in a mouse model of epilepsy.

Li H, Viskaitis P, Bracey E, Peleg-Raibstein D, Burdakov D Nat Commun. 2024; 15(1):1249.

PMID: 38341419 PMC: 10858876. DOI: 10.1038/s41467-024-45515-5.